WallStreetZenWallStreetZen

NASDAQ: NTLA
Intellia Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Intellia Therapeutics earnings were -$525.9M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest NTLA earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$114.3M, down 11.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NTLA reported annual earnings of -$519.0M, with 7.9% growth.

NTLA earnings history

Current Revenue
$45.6M
Current Earnings
-$525.9M
Current Profit Margin
-1,154.1%

NTLA Return on Equity

Current Company
-58.7%
Current Industry
-60.2%
Current Market
31.5%
NTLA's Return on Equity (-58.7%)... subscribe to Premium to read more.
High Return on Equity Performance

NTLA undefined

Current Company
-46.3%
Current Industry
-2.5%
NTLA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NTLA announces earnings.

NTLA undefined

Current Company
-60.2%
Current Industry
5.8%
NTLA's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NTLA vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NTLA-$515.64M-$525.91MN/A-$5.22
ARDX-$31.70M-$53.76MN/A-$0.22
QURE-$138.01M-$217.58MN/A-$4.39
SNDX-$317.31M-$331.20MN/A-$3.85
ZYME-$94.99M-$113.68MN/A-$1.50
View Top Biotech Stocks

Intellia Therapeutics Earnings Reports & History FAQ

What were Intellia Therapeutics's earnings last quarter?

On NTLA's earnings call on Invalid Date, Intellia Therapeutics (NASDAQ: NTLA) reported Q1 2025 earnings per share (EPS) of -$1.10, up 1.79% year over year. Total NTLA earnings for the quarter were -$114.33 million. In the same quarter last year, Intellia Therapeutics's earnings per share (EPS) was -$1.12.

If you're new to stock investing, here's how to buy Intellia Therapeutics stock.

Is Intellia Therapeutics profitable or losing money?

As of the last Intellia Therapeutics earnings report, Intellia Therapeutics is currently losing money. Intellia Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$525.91 million, a 8.32% increase year over year.

What was NTLA's earnings growth in the past year?

As of Intellia Therapeutics's earnings date in Invalid Date, Intellia Therapeutics's earnings has grown year over year. NTLA earnings in the past year totalled -$525.91 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.